Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "credit fc26 Visitez le site Buyfc26coins.com La référence incontestée pour les FC 26 coins.VIiF"

Looking for quality documents?
external link icon
Repligen To Host Investor Day 2022
WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen Investor Day 2022” on Tuesday, September 20. The live event will take place at the Nasdaq MarketSite in New York City from 8:20 to 11:30 a.m. EDT. The event will feature presentations by several members of the company’s leadership team and will include Q&A discussion between the audience and Repligen panel members. A live webcast of “Repligen Investor Day 2022” will be accessible through the Investor Relations website at www.repligen.com and will be available for replay for a limited period of time following the event. In-person event registration is limited to institutional investors and analysts, while webcast registration is available to all. About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing
external link icon
Repligen Reports Second Quarter 2018 Financial Results
Record quarterly revenue of $47.7 million represents 47% year-over-year growth Revenue guidance raised to $185-$190 million for full year 2018 WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter and first half of 2018. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2018, updates to our 2018 financial guidance and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “Our second quarter financial performance was led by record direct sales of our filtration and chromatography products, which nearly doubled year-over-year and delivered greater than 25% organic growth. Our Spectrum products continue to perform well, with 29% pro forma growth over the second quarter of 2017. In our Proteins franchise, we
corporate icon
Biologics
Challenge: Complex upstream systems require continuous nutrient profiling and metabolite monitoring to prevent culture collapse or batch failure. Traditional sampling methods are time-consuming and disruptive. Our Solution: REBEL XT and Maven enable real-time profiling of amino acids, glucose, lactate, and ammonia to ensure optimal feed strategies and cellular performance.
external link icon
Repligen Reports Second Quarter 2024 Financial Results
Reports second quarter revenue of $154 million Second quarter orders of $157 million Book-to-bill 1.02 for the quarter, 1.01 year-to-date Achieved first half revenue and order targets Narrows revenue guidance within previous range for fiscal year 2024; adjusted EPS guidance unchanged
WALTHAM, Mass., July 30, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) of 2024, covering the three- and six- month periods ended June 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and access information for today’s webcast and conference call. Tony J. Hunt, Chief Executive Officer of Repligen said, “We delivered solid second quarter revenue of $154 million and first half revenue of $305 million, achieving our year-to-date sales target. We are very encouraged by orders in the
external link icon
Repligen Reports Fourth Quarter and Full Year 2020 Financial Results
Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growth
Organic revenue growth was 47% for the fourth quarter and 29% for the year 2020 WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2020. Provided in this press release are financial highlights for the three - and twelve-month periods ended December 31, 2020, followed by our current financial guidance for the year 2021, and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are delighted with the way we finished off 2020 with 47% organic growth in the fourth quarter and 29% for the full year. Sales into COVID vaccine and therapeutic accounts were a major contributor to overall
external link icon
Repligen Reports Fourth Quarter and Year 2015 Financial Results
- Constant currency revenue growth of 45% for the fourth quarter, 47% for the year -
- Gross margin expansion of 420 basis points to 57.8% for the year -
- Non-GAAP adjusted EPS of $0.40, an increase of 67% for the year - WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the fourth quarter and year ended December 31, 2015. Below are the Company's performance highlights for these periods, followed by financial guidance for the year 2016 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “2015 was a great year for Repligen, as we executed on our growth strategy and established the Repligen brand in key bioprocessing end-markets, while delivering strong financial performance across all of our product lines. For the year, we reported exceptional product sales
external link icon
Repligen Announces Strategic Focus on Bioprocessing Business and Reports Second Quarter 2012 Financial Results
Repligen Corporation (NASDAQ: RGEN) today reported financial results for its second quarter and year-to-date period ended June 30, 2012. In addition, the Company announced that it will focus its corporate strategy and resources on the growth of its core bioprocessing business, which achieved record sales during the quarter. As a result of this defined strategic focus, the Company will seek a development and commercialization partner for its pancreatic imaging product candidate, RG1068. The Company reported total revenue for the three-month period ended June 30, 2012 of $15,524,000 compared to $7,654,000 for the same period in 2011. Revenue growth for the second quarter of 2012 was driven by the Company’s expanded bioprocessing business, which generated $11,659,000 in product revenue compared to $4,358,000 for the same period in 2011, an increase of 168%. Royalty and research revenue for the three-month period ended June 30, 2012, consisting primarily of royalty payments from
external link icon
Repligen Announces Agreement to Acquire Engineered Molding Technology
Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Albany, New York based Engineered Molding Technology (“EMT”), an innovator and manufacturer of single-use silicone assemblies and components used in the manufacturing of biologic drugs. EMT’s standard and custom molded and over-molded connectors and silicone tubing products are key components in single-use filtration and chromatography systems.
Tony J. Hunt, President and CEO of Repligen, said, “The acquisition of EMT expands our line of single-use ProConnex® flow paths, streamlines our supply chain for ATF, and gives us more flexibility as we scale and expand our single-use and systems portfolios.” He continued, “The EMT portfolio also enables us to offer bioprocessing customers
external link icon
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. Mr. Loeillot joins Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the
external link icon
Repligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a public offering price of $64.00 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 410,156 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 3, 2019 subject to customary closing conditions.
J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering. Janney Montgomery Scott is acting as lead manager for the offering. These securities
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support